American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
NEW YORK, Aug. 25, 2017 -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada.
The Phase II clinical trial will investigate the effect of ZLX-1 on insomnia, and is a critical milestone for this novel insomnia treatment on its way to final approval. The trial results are essential for validating the ZLX-1 concept and for designing the Phase IIb trial to follow.
“We are thrilled to finally see the the clinical trial taking off,” says Blake Insomnia Therapeutics president and CEO Birger Jan Olsen. “It is an important milestone for the company and also for me personally, as I’ve been looking forward to this moment for quite some time now.”
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact: Birger Jan Olsen, CEO Blake Insomnia Therapeutics Inc. 1(888) 612-2905 [email protected]
